| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25,730 |
21,418 |
$2.20M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,793 |
7,728 |
$1.03M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,776 |
3,573 |
$393K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,272 |
3,083 |
$342K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,248 |
2,932 |
$312K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,792 |
1,648 |
$238K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,504 |
1,403 |
$175K |
| D1206 |
Topical application of fluoride varnish |
4,573 |
4,194 |
$106K |
| 92552 |
|
3,899 |
3,624 |
$96K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,909 |
4,579 |
$67K |
| 90686 |
|
2,976 |
2,795 |
$62K |
| 90698 |
|
2,272 |
2,109 |
$49K |
| 99215 |
Prolong outpt/office vis |
312 |
293 |
$46K |
| 90670 |
|
1,789 |
1,632 |
$38K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,793 |
1,602 |
$38K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
764 |
666 |
$36K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,897 |
2,700 |
$35K |
| 92551 |
|
3,573 |
3,379 |
$32K |
| 90677 |
|
478 |
467 |
$27K |
| 94760 |
|
12,792 |
10,670 |
$24K |
| 96127 |
|
2,839 |
2,645 |
$24K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,097 |
1,068 |
$23K |
| 90680 |
|
1,072 |
989 |
$23K |
| 99177 |
|
3,872 |
3,494 |
$18K |
| 99381 |
|
158 |
139 |
$17K |
| 90633 |
|
701 |
663 |
$15K |
| 90744 |
|
631 |
594 |
$14K |
| 90710 |
|
500 |
470 |
$11K |
| 99173 |
|
3,872 |
3,755 |
$9K |
| 99050 |
|
1,005 |
887 |
$9K |
| 99401 |
|
298 |
195 |
$8K |
| 99051 |
|
2,208 |
1,960 |
$8K |
| 90651 |
|
329 |
301 |
$7K |
| 87807 |
|
640 |
581 |
$6K |
| 0071A |
|
125 |
111 |
$5K |
| 90656 |
|
187 |
186 |
$4K |
| 90661 |
|
136 |
136 |
$4K |
| 90734 |
|
159 |
124 |
$4K |
| 90696 |
|
140 |
129 |
$3K |
| 90619 |
|
99 |
99 |
$3K |
| 90715 |
|
126 |
104 |
$3K |
| 0072A |
|
61 |
57 |
$2K |
| 90620 |
|
97 |
81 |
$2K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
339 |
318 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
13 |
13 |
$2K |
| 96160 |
|
537 |
527 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$1K |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
81 |
81 |
$760.00 |
| 0001A |
|
14 |
14 |
$520.00 |
| 91307 |
|
243 |
189 |
$517.58 |
| 96161 |
|
155 |
150 |
$428.01 |
| 3008F |
|
1,013 |
847 |
$390.00 |
| 90716 |
|
14 |
12 |
$325.92 |
| 90688 |
|
16 |
15 |
$325.92 |
| W7000 |
|
65 |
58 |
$262.24 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
18 |
14 |
$142.52 |
| 81002 |
|
48 |
46 |
$98.17 |
| 99000 |
|
743 |
668 |
$68.84 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
16 |
14 |
$1.50 |
| 91300 |
|
15 |
14 |
$0.00 |
| 36416 |
|
1,258 |
1,117 |
$0.00 |